Bill Title: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Spectrum: Partisan Bill (Republican 2-0)

Status: (Introduced) 2023-10-06 - Referred to the Subcommittee on Health. [HB5850 Detail]

Text: Latest bill text (Introduced) [PDF]

---

Voting Records

Chamber	Vote	Date	Yea	Nay	NV	Abs	Total	Result	Source	View
No roll call record information currently on file.

States not producing parsable votes may be available as images in Supplemental Documents.

Social Comments on US HB5850